Limited impact of EU Paediatric Regulation on Finnish clinical trials highlights need for Nordic collaboration

被引：6

作者：

Korppi, Matti ^{[1
,2
]}

Lepola, Pirkko ^{[3
]}

Vettenranta, Kim ^{[4
]}

Pakkala, Seppo ^{[5
]}

Hoppu, Kalle ^{[4
,6
,7
]}

机构：

[1] Tampere Univ, Tampere Ctr Child Hlth Res, Tampere 33014, Finland

[2] Univ Hosp, Tampere, Finland

[3] Tampere Univ, Finnish Investigators Network Pediat Med, Tampere Ctr Child Hlth Res, Clin Res Inst Helsinki Univ Cent Hosp Ltd, Tampere 33014, Finland

[4] Hosp Dist Helsinki & Uusimaa HUS, Hosp Children & Adolescents, Helsinki, Finland

[5] Clin Res Inst Helsinki Univ Cent Hosp Ltd, Helsinki, Finland

[6] Univ Helsinki, Dept Clin Pharmacol, SF-00250 Helsinki, Finland

[7] Helsinki Univ Cent Hosp, Poison Informat Ctr, Helsinki, Finland

来源：

ACTA PAEDIATRICA | 2013年 / 102卷 / 11期

关键词：

Clinical trial; EU regulation; Paediatric medicines; Research network; CHILDREN RESEARCH NETWORK; MEDICINES; GLOBALIZATION; LABEL; WARDS;

D O I：

10.1111/apa.12372

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

The Finnish Investigators Network for Paediatric Medicines (FINPEDMED) was established in 2007, to meet the expected increase in paediatric clinical trials following the new EU Paediatric Regulation. Between 2007 and 2012, FINPEDMED received 91 trial requests, 18 trials were started, and in 24 cases, Finnish investigators were not selected by sponsors. ConclusionThis experience from Finland highlights the need for Nordic collaboration to increase expertise, recruitment base and attractiveness for sponsors.

引用

页码：1035 / 1040

页数：6

共 50 条

[41] Clinical Trial Data Transparency in the EU: Is the New Clinical Trials Regulation a Game-Changer?
Żaneta Zemła-Pacud
Gabriela Lenarczyk
IIC - International Review of Intellectual Property and Competition Law, 2023, 54 : 732 - 763
[42] Changes in the German Medicinal Product Act imposed by the EU regulation on clinical Trials
Nickel, Lars
Seibel, Yvonne
Frech, Marion
Sudhop, Thomas
BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2017, 60 (08) : 804 - 811
[43] Clinical Trial Data Transparency in the EU: Is the New Clinical Trials Regulation a Game-Changer?
Zemla-Pacud, Zaneta
Lenarczyk, Gabriela
IIC-INTERNATIONAL REVIEW OF INTELLECTUAL PROPERTY AND COMPETITION LAW, 2023, 54 (05) : 732 - 763
[44] IMPLEMENTATION OF THE NEW EU CLINICAL TRIALS REGULATION IN SLOVAKIA: TASKS AND CHALLENGES FOR THE DISCIPLINE OF CLINICAL PHARMACOLOGY
Glasova, H.
Glasa, J.
Sobonova, K.
Krcmeryova, T.
Holoman, J.
CLINICAL THERAPEUTICS, 2015, 37 (08) : E149 - E149
[45] Industry Collaboration and Primary Guest Authorship of High-Impact Clinical Trials
Roper, Nitin
Korenstein, Deborah
JOURNAL OF GENERAL INTERNAL MEDICINE, 2016, 31 (01) : 12 - 12
[46] Industry Collaboration and Primary Guest Authorship of High-Impact Clinical Trials
Nitin Roper
Deborah Korenstein
Journal of General Internal Medicine, 2016, 31 : 12 - 12
[47] Clinical trial challenges - impact of the new clinical trial regulation on the conduct of clinical trials
Mugosa, Snezana
Glusica, Anja
VOJNOSANITETSKI PREGLED, 2022, 79 (09) : 918 - 923
[48] Simplified consent in cluster randomised trials: the new EU Clinical Trials Regulation does not provide sufficient guidance
Goldstein, Cory E.
van der Graaf, Rieke
BMJ-BRITISH MEDICAL JOURNAL, 2023, 382
[49] Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use: an overview
Petrini, Carlo
ANNALI DELL ISTITUTO SUPERIORE DI SANITA, 2014, 50 (04): : 317 - 321
[50] GENDER AND CLINICAL TRIALS: IS THE REGULATION N. 536/2914 (EU) A MISSED OPPORTUNITY?
Fasan, Marta
Reale, Carla Maria
BIOLAW JOURNAL-RIVISTA DI BIODIRITTO, 2022, (04): : 251 - 276

← 1 2 3 4 5 →